Mature results of a randomized trial of two doses of cisplatin for the treatment of ovarian cancer

Journal of Clinical Oncology

Volumn 14, Issue 7, 1996, Pages 2113-2119

  Kaye, S B ^a   Paul, J ^a   Cassidy, J ^a   Lewis, C R ^a   Duncan, I D ^a   Gordon, H K ^a   Kitchener, H C ^a   Cruickshank, D J ^a   Atkinson, R J ^a   Soukop, M ^a   Rankin, E M ^a   Davis, J A ^a   Reed, N S ^a   Crawford, S M ^a   MacLean, A ^a   Parkin, D ^a   Sarkar, T K ^a   Kennedy, J ^a   Symonds, R P ^a  

^a BEATSON WEST OF SCOTLAND CANCER CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE;

ADULT; ADVANCED CANCER; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SCREENING; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NEUROTOXICITY; OVARY CANCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 8944243551     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1996.14.7.2113     Document Type: Article

References (16)

1. Kaye SB, Lewis CR, Paul J, et al: Randomised study of two doses of cisplatin with cyclophosphamide in epithelial ovarian cancer. Lancet 340:329-333, 1992
2. McGuire WP, Hoskins WJ, Brady MF, et al: An assessment of dose intense therapy in suboptimally debulked ovarian cancer: A Gynaecologic Oncology Group study. J Clin Oncol 13:1589-1599, 1995
3. Armitage P, Berry G: Statistical method in medical research (ed 2). Cambridge, MA, Blackwell Scientific Publications, 1987, pp 421-438
4. Collett D: Modelling survival data in medical research. New York, NY, Chapman & Hall, 1994, pp 223-236
5. Holmgren L, O'Reilly MS, Folkman J: Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1:149-152, 1995
6. Wood WC, Budman DR, Korzum AH, et al: Dose and dose intensity of adjuvant chemotherapy of stage II node positive breast carcinoma. New Engl J Med 330:1253-1259, 1994
7. Jakobsen A: A dose intensity study of carboplatin in ovarian cancer. Int J Gynecol Cancer 5:11, 1995 (suppl 1)
8. Ngan HYS, Choo YC, Cheung M, et al: A randomized study of high-dose versus low-dose cisplatinum combined with cyclophosphamide in the treatment of advanced ovarian cancer. Chemotherapy 35:221-227, 1989
9. Bella M, Coconni G, Leonardi R, et al: Mature results of a prospective randomized trial comparing two different dose-intensity regimens for cisplatin in advanced ovarian carcinoma. Ann Oncol 5:2, 1994 (suppl 8; abstr)
10. Ehrlich CE, Einhorn L, Stehman FB, et al: Treatment of advanced epithelial ovarian cancer using cisplatin, Adriamycin and cytoxan, The Indiana University experience. Clin Obstet Gynecol 10:325-335, 1983
11. Colombo N, Pittelli MR, Parma G, et al: Cisplatin dose-intensity in advanced ovarian cancer: a randomised study of conventional dose-intense versus standard dose cisplatin monochemotherapy. Proc Am Soc Clin Oncol 12:255, 1993 (abstr)
12. Bruzzone M, Catsafados A, Gadduci A, et al: Relationship between cisplatin dose-intensity and treatment outcome in advanced ovarian cancer (AOC) patients. Ann Oncol 5:101, 1994 (suppl 8; abstr)
13. Perez RP, O'Dwyer PJ, Handel L, et al: Comparative cytotoxicity of CI-973, cisplatin, carboplatin and tetraplatin in human ovarian cancer cell lines. Int J Cancer 48:265-269, 1991
14. Hakes TB, Chalas E, Hoskins WJ, et al: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45:284-289, 1992
15. Horwitz SB, Rao S, Ya C-P, et al: Mechanisms of resistance in Paclitaxel, in McGuire WP and Rowinsky EK (eds): Paclitaxel in Cancer Treatment. New York, NY, Dekker, 1995, pp 45-54
16. Andrews PA, Howell SB: Cellular pharmacology of cisplatin: Perspectives on mechanisms of acquired resistance. Cancer Cells 2:35-43, 1990